HC Wainwright reaffirmed their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $110 ...

Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the appointment of Maninder ...

In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target of $20.00. Discover outperforming stocks and invest ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Morgan Stanley upgrades Vir Biotechnology to Overweight with a $20 price target. Get Pro-Level Earnings Insights Before the Market Moves Data show encouraging preliminary safety and efficacy ...

In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller ...